Clinical Trial Update: Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether extended-dose interval immunotherapy provides similar or better efficacy and safety compared with standard-dose i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Triple -Negative Breast Cancer, Breast Cancer | Phase 2 | Status: RECRUITING